lundi 25 novembre 2019

Onco Actu du 25 novembre 2019


3.1.1 PRÉVENTION - TABAC - E-CIGS



Massive Irony: American Heart Association is Lying to the Public in a Campaign Attacking E-Cigarette Companies for Lying [The Rest of the Story]











Trump Warns a Flavor Ban Would Spawn Counterfeit Vaping Products [NY Times]











How Juul Hooked a Generation on Nicotine [NY Times]










Trump says ban of some flavored e-cigarette products could lead to illegal sales [Reuters]











3.3 PRÉVENTION - VACCINS



New Cochrane Review assesses different HPV vaccines and vaccine schedules in adolescent girls and boys [Wiley]











4.1 DÉP., DIAG. & PRONO. - PROSTATE



Commercial Prognostic Tests for Prostate Cancer May Not Be Accurate in African American Men [AACR]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



Consumer DNA Testing May Be the Biggest Health Scam of the Decade [Gizmodo]











5.12.13 IMMUNOTHÉRAPIES - BIOMARQUEURS



Using Artificial Intelligence to determine whether immunotherapy is working [Case Western Reserve University]











5.12.4 IMMUNOTHÉRAPIES - ESSAIS



Major trial backs immunotherapy as standard first-line treatment for head and neck cancer [Institute of Cancer Research]










5.16 TRAITEMENTS - CHIRURGIE



Early removal of slow-growing brain tumours dramatically improves survival [University College London]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Calquence OK boosts AstraZeneca's challenge to Imbruvica [Biopharma Dive]











EMA Recommends Extension of Indications for Lenalidomide [ESMO]











AstraZeneca scores again: Calquence approved for CLL as BTK race heats up [EndPoints]











AstraZeneca shares rise on early U.S. approval for leukemia drug [Reuters]











5.4 TRAITEMENTS - ECONOMIE



Teva to Resume Production of Critical Pediatric Oncology Drug: Too Little, Too Late [Bill of Health]











5.6.17 ESMO - FOIE



Atezolizumab in Combination with Bevacizumab Provides Superior Outcome Compared with Sorafenib in Unresectable HCC [ESMO]










Roche presents pivotal data demonstrating Tecentriq in combination with Avastin improves overall survival in people with the most common form of liver cancer [Roche]











Roche says Tecentriq cocktail helps liver cancer patients live longer [Reuters]











5.6.4 ESMO - POUMON



Takeda eyes Alunbrig earlier lung cancer use as 2-year data trounce Pfizer’s Xalkori [Fierce Pharma]











Takeda announces positive new ALK+ lung cancer data as list of crizotinib successors widens [EndPoints]










Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up [Takeda]











Takeda says cancer drug Alunbrig shows longer benefit vs. crizotinib [Reuters]











5.6.6 ESMO - SEIN



First China-manufactured Trastuzumab Biosimilar HLX02 Global Phase III Trial Met Primary Endpoint in Breast Cancer [ESMO]











6. LUTTE CONTRE LES CANCERS



A Cancer Care Approach Tailored To The Elderly May Have Better Results [NPR]










Oncologist Azra Raza: ‘Don’t give up hope. Don’t give in to despair’ [The Guardian]











6.1 OBSERVATION



Unique Factors Impact Outcome in AYA Patients with Cancer [ESMO]










Cancer: One in five cancer diagnoses 'in Emergency Departments' [BBC News]











Cancer patients have an up to ten times increased risk of dying of heart disease, major research shows [The Telegraph]











6.10.1 POLITIQUES (USA)



Trump says he will allow states to import prescription drugs to lower costs [Reuters]











6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES



Toni Bark has cancer [Respectful Insolence]